JP7627687B2 - Ｌｉｌｒｂ２に対するシングルドメイン抗体 - Google Patents

Ｌｉｌｒｂ２に対するシングルドメイン抗体 Download PDF

Info

Publication number
JP7627687B2
JP7627687B2 JP2022517990A JP2022517990A JP7627687B2 JP 7627687 B2 JP7627687 B2 JP 7627687B2 JP 2022517990 A JP2022517990 A JP 2022517990A JP 2022517990 A JP2022517990 A JP 2022517990A JP 7627687 B2 JP7627687 B2 JP 7627687B2
Authority
JP
Japan
Prior art keywords
amino acid
sdab
seq
lilrb2
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548764A (ja
JP2022548764A5 (enExample
Inventor
ルストー，マリア
ユノー，リーズ
ラングラード－デモイエン，ピエール
コーマルタン，ジュリアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invectys SAS
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Publication of JP2022548764A publication Critical patent/JP2022548764A/ja
Publication of JP2022548764A5 publication Critical patent/JP2022548764A5/ja
Application granted granted Critical
Publication of JP7627687B2 publication Critical patent/JP7627687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
JP2022517990A 2019-09-20 2020-09-18 Ｌｉｌｒｂ２に対するシングルドメイン抗体 Active JP7627687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306148.8 2019-09-20
EP19306148 2019-09-20
PCT/EP2020/076198 WO2021053199A1 (en) 2019-09-20 2020-09-18 Single-domain antibodies directed against lilrb2

Publications (3)

Publication Number Publication Date
JP2022548764A JP2022548764A (ja) 2022-11-21
JP2022548764A5 JP2022548764A5 (enExample) 2023-09-25
JP7627687B2 true JP7627687B2 (ja) 2025-02-06

Family

ID=68654426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517990A Active JP7627687B2 (ja) 2019-09-20 2020-09-18 Ｌｉｌｒｂ２に対するシングルドメイン抗体

Country Status (11)

Country Link
US (1) US20230235050A1 (enExample)
EP (1) EP4031572A1 (enExample)
JP (1) JP7627687B2 (enExample)
KR (1) KR20220128332A (enExample)
CN (1) CN115066435B (enExample)
AU (1) AU2020351274A1 (enExample)
BR (1) BR112022004534A2 (enExample)
CA (1) CA3154450A1 (enExample)
IL (1) IL291506A (enExample)
MX (1) MX2022003365A (enExample)
WO (1) WO2021053199A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119156229A (zh) * 2022-03-04 2024-12-17 D2M生物治疗有限公司 抗lilrb1/2抗体及其用途
CN114805580B (zh) * 2022-06-28 2022-09-06 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN115975029B (zh) * 2022-06-28 2026-05-29 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
WO2024022462A1 (zh) * 2022-07-29 2024-02-01 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
AU2023328075A1 (en) * 2022-08-22 2025-04-03 Antengene Biologics Limited Novel anti-lilrb2 antibodies and uses thereof
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN116789826A (zh) * 2023-05-12 2023-09-22 南京师范大学 抗人lilrb2全人源单域抗体及其应用
CN116789825B (zh) * 2023-05-12 2026-06-02 南京师范大学 抗lilrb1/lilrb2的全人源单域抗体及其应用
CN119176874A (zh) * 2023-06-21 2024-12-24 康源博创生物科技(北京)有限公司 一种能够结合lilrb2的抗体或其抗原结合片段
CN119619509A (zh) * 2023-09-05 2025-03-14 中日友好医院(中日友好临床医学研究所) 一种结直肠癌治疗靶点和血清标志物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016144728A2 (en) 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
US20190194327A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
WO2019144052A1 (en) 2018-01-18 2019-07-25 Adanate, Inc. Anti-lilrb antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
EP2160409A1 (en) * 2007-05-24 2010-03-10 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016144728A2 (en) 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
US20190194327A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
WO2019144052A1 (en) 2018-01-18 2019-07-25 Adanate, Inc. Anti-lilrb antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hui-Ming CHEN，locking immunoinhibitory receptor LILRB2 reprograms tumorassociated myeloid cells and promotes antitumor immunity，The Journal of Clinical Investigation，米国，2018年10月22日，128(12)，pp.5647-5662，https://doi.org/10.1172/JCI97570

Also Published As

Publication number Publication date
CN115066435B (zh) 2025-05-02
US20230235050A1 (en) 2023-07-27
JP2022548764A (ja) 2022-11-21
KR20220128332A (ko) 2022-09-20
CA3154450A1 (en) 2021-03-25
IL291506A (en) 2022-05-01
EP4031572A1 (en) 2022-07-27
BR112022004534A2 (pt) 2022-06-07
AU2020351274A1 (en) 2022-05-05
CN115066435A (zh) 2022-09-16
MX2022003365A (es) 2022-08-22
WO2021053199A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CN115066435B (zh) 针对lilrb2的单域抗体
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
JP2022514197A (ja) 抗ｂ７－ｈ３抗体
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
TW201932491A (zh) 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途
TWI902681B (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
TW202043278A (zh) 結合ｐｄ－ｌ１和ｏｘ４０的雙特異性抗體
TWI836070B (zh) 抗trop-2抗體、其抗原結合片段及其醫藥用途
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
JP2022511311A (ja) ヒトｐｄ‐ｌ１抗体
CN117242092A (zh) Vegfa结合分子
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
JP2025521541A (ja) 単離された抗原結合タンパク質及びその使用
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
TW202413422A (zh) 抗體、其抗原結合片段及其藥物用途
KR20190135478A (ko) 항 gpr20 항체
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
JP2023511189A (ja) Ｓｅｍｇ２抗体およびその使用
EA046196B1 (ru) Однодоменные антитела, направленные против lilrb2
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2011052753A1 (ja) Mansc1蛋白質に結合し、抗癌活性を有する抗体
HK40068066A (en) Anti-nectin-4 antibodies and bispecific antibodies
KR20240004375A (ko) Il-38-특이적 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250127

R150 Certificate of patent or registration of utility model

Ref document number: 7627687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150